[Hormonal life in systemic lupus and other connective tissue diseases].
Among connective tissue diseases, systemic lupus erythematosus is the illness that is most concerned by hormonal life events. The sex ratio is 9/1, and symptoms begin mostly during the third decade, sometimes during birth pill contraception or during pregnancy. As soon as systemic lupus is under control of an efficient treatment, pregnancy is no longer contra-indicated. A medical multidisciplinary surveillance is required. Complicated pregnancy concerns mother and baby. Lupus flares are more frequent during the second and third trimesters as well as during the post-partum period. Usually the intensity is moderate. Severe flares concern patients with renal involvement, hypertension and renal insufficiency and are mostly seen in patients with unplanified pregnancy and yet with still active lupus. Foetal death occurs in 10-30% of the cases, depending on the lupus activity and severity (renal lupus). Prematurity remains an important cause of morbidity (30% of live births). Foetal deaths and prematurity are even more frequent if the patient has an antiphospholipid syndrome. Neonatal cutaneous lupus and auriculo-ventricular congenital heart block is infrequent (1% of SLE patients with anti-Ro/SSA antibodies). Among other connective tissue diseases, polymyositis has a very severe obstetrical prognosis for both mother and foetus. Among primary vasculitis, polyarteritis nodosa, as found during pregnancy, can herald a very bad prognosis.
D000818:Animals; D016736:Antiphospholipid Syndrome; D003240:Connective Tissue Diseases; D003271:Contraceptive Agents, Female; D015914:Estrogen Replacement Therapy; D005260:Female; D005313:Fetal Death; D006728:Hormones; D006801:Humans; D008180:Lupus Erythematosus, Systemic; D008593:Menopause; D011247:Pregnancy; D011248:Pregnancy Complications; D012595:Scleroderma, Systemic
D003271:Contraceptive Agents, Female; D006728:Hormones